OncologyEducation presents MedOncNow
In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.
21 Episoder
Kommentarer
0Vær den første til å kommentere
Registrer deg nå og bli medlem av OncologyEducation presents MedOncNow sitt community!